NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology
Globe Newswire•08/10/2026•16:01 ET
0
Key Highlights
- ➤NIH grant totals approximately $1 million for first year, with additional funding expected
- ➤NeuroOne (NMTC) will receive approximately $200,000 through April 30, 2027
- ➤Dartmouth-led team advances integrated sub-second neurotransmitter sensors in humans
- ➤Collaboration combines sensing with NeuroOne’s sEEG electrodes for real-time brain monitoring
Expert Statements
Dave Rosa, CEO of NeuroOne
“We are excited to collaborate with Dartmouth on this NIH-supported initiative.”
Dave Rosa, CEO of NeuroOne
“This grant is another compelling example of the versatility and potential of NeuroOne’s thin-film electrode technology platform.”
Dave Rosa, CEO of NeuroOne
“While our technology has already demonstrated value in recording, stimulation, and therapeutic applications, we believe its flexible design and high-performance characteristics create opportunities well beyond those uses.”
New NIH Award will Initially Provide NeuroOne Approximately $200,000 through April 2027
EDEN PRAIRIE, Minn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced it has entered into a research and development subaward agreement with Dartmouth to support the advancement of next-generation neurotransmitter sensing technology.
Get started
Create a free account to read the full story.